Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | VNN1 | O95497 | 2/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24942218 | 1.00 | HPGD (0.50) | HPGDMGLLVNN1DDR1LRRK2 | |
| SCHEMBL23675350 | 0.86 | HPGD (0.52) | HPGDMGLLVNN1DDR1LRRK2 | |
| SCHEMBL24463672 | 0.86 | HPGD (0.52) | HPGDMGLLVNN1DDR1LRRK2 | |
| SCHEMBL23675278 | 0.85 | HPGD (0.51) | HPGDMGLLVNN1DDR1LRRK2 | |
| SCHEMBL29564966 | 0.85 | HPGD (0.51) | HPGDMGLLVNN1DDR1LRRK2 | |
| SCHEMBL30201439 | 0.84 | HPGD (0.50) | HPGDMGLLVNN1DDR1LRRK2 | |
| SCHEMBL31038242 | 0.84 | HPGD (0.50) | HPGDMGLLVNN1DDR1LRRK2 | |
| SCHEMBL24942616 | 0.84 | HPGD (0.50) | HPGDMGLLVNN1DDR1LRRK2 | |
| SCHEMBL23675201 | 0.84 | HPGD (0.54) | HPGDMGLLVNN1DDR1LRRK2 | |
| SCHEMBL24329043 | 0.84 | HPGD (0.54) | HPGDMGLLVNN1DDR1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294519-A1 | PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. | 2024-09-05 | — | — | US | disclosed |
| EP-4376841-A1 | PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | Epirium Bio Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023009642-A1 | PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294519-A1 | PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGIS | HPGD 1/4885MGLL 1025/4885VNN1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.